# Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

> **NCT07401992** · PHASE4 · RECRUITING · sponsor: **Hospital Universitario Dr. Jose E. Gonzalez** · enrollment: 62 (estimated)

## Conditions studied

- Psoriasis (PsO)
- Obesity & Overweight
- Diabetes Mellitus - Type 2

## Interventions

- **DRUG:** Semaglutide (Rybelsus®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07401992
- **Lead sponsor:** Hospital Universitario Dr. Jose E. Gonzalez
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07401992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07401992, "Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07401992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*